Co-expression of ER and c-erb B2 in breast cancer

Sunil Badve, C. G. Deshpande, A. Gupta, E. L. Wiley, V. C. Jordan

Research output: Contribution to journalArticle

Abstract

Determination of the estrogen receptor (ER) status is done in the management of breast cancer as ER positive tumors have a favorable prognosis and are likely to respond to anti-estrogenic agents such as Tamoxifen (Tarn). However, ER positive tumors when treated with Tam may show innate or acquired resistance. In cell culture experiments, transfection of MCF-7 cells, an ER positive estrogen dependent breast cancer cell line, with c-erb-B2 expression vector results in Tam-resistance. Additionally, experimental data exists that shows that c-erb-b2 gene is transcriptionally repressed by estrogen stimulation, an effect reversed by tamoxifen. A strong relationship exists between c-erb-B2 positivity and ER negativity i.e. tumors that have escaped their dependence on estrogen for growth. A recent study based on microarray analysis has suggested the breast cancer can be sub-classified into mutually distinct groups based on ER and c-erbB2 expression. These in vitro data and clinical studies in human breast cancer have led to suggestions that c-erb B2 expression in ER positive tumors may be a marker of tamoxifen resistance. Methods: We retrospectively analyzed a series of 474 patients of breast cancer for expression of ER and c-erb B2. 77 cases had been reported as expressing both these biomarkers. These cases were reanalyzed and a representative set re-stained for both these markers using Dako's Dual staining kit. Results: Reexamination of these cases on serial sections IHC and by dual staining IHC showed co-expression of ER and c-erb b2 molecules in all the cases. In an individual case varying percentage of four distinct cell populations (ER+ c-erb b2-; ER- c-erb b2+; ER+ c-erb 2+; and both negative) and were identified. Conclusions: Human breast cancer is composed of mixed population of tumor cells that may or may not show expression of ER and c-erb b2. Co-expression of these molecules is seen in a percentage of cases (16.2%).

Original languageEnglish
Pages (from-to)296
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Estrogens
Tamoxifen
Neoplasms
Staining and Labeling
MCF-7 Cells
Microarray Analysis
Population
Transfection
Cell Culture Techniques
Biomarkers
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Badve, S., Deshpande, C. G., Gupta, A., Wiley, E. L., & Jordan, V. C. (2001). Co-expression of ER and c-erb B2 in breast cancer. Breast Cancer Research and Treatment, 69(3), 296.

Co-expression of ER and c-erb B2 in breast cancer. / Badve, Sunil; Deshpande, C. G.; Gupta, A.; Wiley, E. L.; Jordan, V. C.

In: Breast Cancer Research and Treatment, Vol. 69, No. 3, 2001, p. 296.

Research output: Contribution to journalArticle

Badve, S, Deshpande, CG, Gupta, A, Wiley, EL & Jordan, VC 2001, 'Co-expression of ER and c-erb B2 in breast cancer', Breast Cancer Research and Treatment, vol. 69, no. 3, pp. 296.
Badve S, Deshpande CG, Gupta A, Wiley EL, Jordan VC. Co-expression of ER and c-erb B2 in breast cancer. Breast Cancer Research and Treatment. 2001;69(3):296.
Badve, Sunil ; Deshpande, C. G. ; Gupta, A. ; Wiley, E. L. ; Jordan, V. C. / Co-expression of ER and c-erb B2 in breast cancer. In: Breast Cancer Research and Treatment. 2001 ; Vol. 69, No. 3. pp. 296.
@article{6f23aa50a8e1401ab36f0cf642b9c7b5,
title = "Co-expression of ER and c-erb B2 in breast cancer",
abstract = "Determination of the estrogen receptor (ER) status is done in the management of breast cancer as ER positive tumors have a favorable prognosis and are likely to respond to anti-estrogenic agents such as Tamoxifen (Tarn). However, ER positive tumors when treated with Tam may show innate or acquired resistance. In cell culture experiments, transfection of MCF-7 cells, an ER positive estrogen dependent breast cancer cell line, with c-erb-B2 expression vector results in Tam-resistance. Additionally, experimental data exists that shows that c-erb-b2 gene is transcriptionally repressed by estrogen stimulation, an effect reversed by tamoxifen. A strong relationship exists between c-erb-B2 positivity and ER negativity i.e. tumors that have escaped their dependence on estrogen for growth. A recent study based on microarray analysis has suggested the breast cancer can be sub-classified into mutually distinct groups based on ER and c-erbB2 expression. These in vitro data and clinical studies in human breast cancer have led to suggestions that c-erb B2 expression in ER positive tumors may be a marker of tamoxifen resistance. Methods: We retrospectively analyzed a series of 474 patients of breast cancer for expression of ER and c-erb B2. 77 cases had been reported as expressing both these biomarkers. These cases were reanalyzed and a representative set re-stained for both these markers using Dako's Dual staining kit. Results: Reexamination of these cases on serial sections IHC and by dual staining IHC showed co-expression of ER and c-erb b2 molecules in all the cases. In an individual case varying percentage of four distinct cell populations (ER+ c-erb b2-; ER- c-erb b2+; ER+ c-erb 2+; and both negative) and were identified. Conclusions: Human breast cancer is composed of mixed population of tumor cells that may or may not show expression of ER and c-erb b2. Co-expression of these molecules is seen in a percentage of cases (16.2{\%}).",
author = "Sunil Badve and Deshpande, {C. G.} and A. Gupta and Wiley, {E. L.} and Jordan, {V. C.}",
year = "2001",
language = "English",
volume = "69",
pages = "296",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Co-expression of ER and c-erb B2 in breast cancer

AU - Badve, Sunil

AU - Deshpande, C. G.

AU - Gupta, A.

AU - Wiley, E. L.

AU - Jordan, V. C.

PY - 2001

Y1 - 2001

N2 - Determination of the estrogen receptor (ER) status is done in the management of breast cancer as ER positive tumors have a favorable prognosis and are likely to respond to anti-estrogenic agents such as Tamoxifen (Tarn). However, ER positive tumors when treated with Tam may show innate or acquired resistance. In cell culture experiments, transfection of MCF-7 cells, an ER positive estrogen dependent breast cancer cell line, with c-erb-B2 expression vector results in Tam-resistance. Additionally, experimental data exists that shows that c-erb-b2 gene is transcriptionally repressed by estrogen stimulation, an effect reversed by tamoxifen. A strong relationship exists between c-erb-B2 positivity and ER negativity i.e. tumors that have escaped their dependence on estrogen for growth. A recent study based on microarray analysis has suggested the breast cancer can be sub-classified into mutually distinct groups based on ER and c-erbB2 expression. These in vitro data and clinical studies in human breast cancer have led to suggestions that c-erb B2 expression in ER positive tumors may be a marker of tamoxifen resistance. Methods: We retrospectively analyzed a series of 474 patients of breast cancer for expression of ER and c-erb B2. 77 cases had been reported as expressing both these biomarkers. These cases were reanalyzed and a representative set re-stained for both these markers using Dako's Dual staining kit. Results: Reexamination of these cases on serial sections IHC and by dual staining IHC showed co-expression of ER and c-erb b2 molecules in all the cases. In an individual case varying percentage of four distinct cell populations (ER+ c-erb b2-; ER- c-erb b2+; ER+ c-erb 2+; and both negative) and were identified. Conclusions: Human breast cancer is composed of mixed population of tumor cells that may or may not show expression of ER and c-erb b2. Co-expression of these molecules is seen in a percentage of cases (16.2%).

AB - Determination of the estrogen receptor (ER) status is done in the management of breast cancer as ER positive tumors have a favorable prognosis and are likely to respond to anti-estrogenic agents such as Tamoxifen (Tarn). However, ER positive tumors when treated with Tam may show innate or acquired resistance. In cell culture experiments, transfection of MCF-7 cells, an ER positive estrogen dependent breast cancer cell line, with c-erb-B2 expression vector results in Tam-resistance. Additionally, experimental data exists that shows that c-erb-b2 gene is transcriptionally repressed by estrogen stimulation, an effect reversed by tamoxifen. A strong relationship exists between c-erb-B2 positivity and ER negativity i.e. tumors that have escaped their dependence on estrogen for growth. A recent study based on microarray analysis has suggested the breast cancer can be sub-classified into mutually distinct groups based on ER and c-erbB2 expression. These in vitro data and clinical studies in human breast cancer have led to suggestions that c-erb B2 expression in ER positive tumors may be a marker of tamoxifen resistance. Methods: We retrospectively analyzed a series of 474 patients of breast cancer for expression of ER and c-erb B2. 77 cases had been reported as expressing both these biomarkers. These cases were reanalyzed and a representative set re-stained for both these markers using Dako's Dual staining kit. Results: Reexamination of these cases on serial sections IHC and by dual staining IHC showed co-expression of ER and c-erb b2 molecules in all the cases. In an individual case varying percentage of four distinct cell populations (ER+ c-erb b2-; ER- c-erb b2+; ER+ c-erb 2+; and both negative) and were identified. Conclusions: Human breast cancer is composed of mixed population of tumor cells that may or may not show expression of ER and c-erb b2. Co-expression of these molecules is seen in a percentage of cases (16.2%).

UR - http://www.scopus.com/inward/record.url?scp=33749112627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749112627&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 296

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -